Ciro Santoro
Overview
Explore the profile of Ciro Santoro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ilardi F, Franzone A, Iapicca C, Manzo R, Angellotti D, Nappa D, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Oct;
25(12):836-844.
PMID: 39445522
Purpose: The prognostic significance of noninvasive myocardial work (MW) indices in patients undergoing transcatheter aortic valve implantation (TAVI) has not been adequately examined. Methods: We retrospectively selected 88 consecutive patients...
2.
Parlati A, Nardi E, Basile C, Paolillo S, Marzano F, Chirico A, et al.
J Public Health Res
. 2024 Oct;
13(4):22799036241278817.
PMID: 39398345
Cardiovascular diseases (CVD) and mental health disorders (MHD) are respectively the first and second most prevalent diseases in high-income countries and the two most relevant causes of disability worldwide. The...
3.
Madaudo C, Parlati A, Di Lisi D, Carluccio R, Sucato V, Vadala G, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Sep;
25(11):766-771.
PMID: 39347723
Artificial intelligence has increasingly become an integral part of our daily activities. ChatGPT, a natural language processing technology developed by OpenAI, is widely used in various industries, including healthcare. The...
4.
Canciello G, Lombardi R, Borrelli F, Ordine L, Chen S, Santoro C, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125703
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained left ventricular hypertrophy (LVH), diastolic dysfunction, and increased sudden-death risk. Early detection of the phenotypic expression of the disease in...
5.
Nardi E, Santoro C, Prastaro M, Canonico M, Paolillo S, Gargiulo G, et al.
Cardiooncology
. 2024 Aug;
10(1):48.
PMID: 39113118
Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and...
6.
Tocchetti C, Farmakis D, Koop Y, Andres M, Couch L, Formisano L, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2055-2076.
PMID: 39087551
The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can...
7.
Fedele T, Orefice S, Fiorillo L, Cuomo V, Capone V, Casciano O, et al.
Eur Heart J Suppl
. 2024 Apr;
22(Suppl N):N135-N137.
PMID: 38626258
Aims: The inability to carry office visits was collateral damage caused by the Coronavirus (COVID-19) pandemic. Tele-health is a relatively new, and yet fundamental amid the current crisis, resource to...
8.
Mancusi C, Basile C, Spaccarotella C, Gargiulo G, Fucile I, Paolillo S, et al.
High Blood Press Cardiovasc Prev
. 2024 Mar;
31(2):127-140.
PMID: 38489152
Heart failure (HF) with preserved ejection fraction (HFpEF) is a prevalent global condition affecting approximately 50% of the HF population. With the aging of the worldwide population, its incidence and...
9.
Manzi L, Sperandeo L, Forzano I, Castiello D, Florimonte D, Paolillo R, et al.
Diagnostics (Basel)
. 2024 Jan;
14(2).
PMID: 38248013
Heart failure (HF) has a global prevalence of 1-2%, and the incidence around the world is growing. The prevalence increases with age, from around 1% for those aged <55 years...
10.
Di Lisi D, Dessalvi C, Zito C, Madaudo C, Manganaro R, Mercurio V, et al.
Curr Probl Cardiol
. 2023 Dec;
49(3):102229.
PMID: 38154703
In recent years, important advances have been made in the field of Cardio-Oncology. The 2022 ESC Guidelines on Cardio-Oncology proposed a baseline cardiovascular risk stratification for cancer patients and preventive...